Research Analysts Set Expectations for XFOR FY2025 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.35) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $3.00 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million.

Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research note on Thursday, March 27th.

X4 Pharmaceuticals Stock Up 2.8 %

Shares of XFOR stock opened at $0.23 on Thursday. X4 Pharmaceuticals has a 12 month low of $0.21 and a 12 month high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The firm has a market cap of $39.59 million, a PE ratio of -2.53 and a beta of 0.58. The stock has a 50 day moving average of $0.42 and a 200-day moving average of $0.51.

Institutional Trading of X4 Pharmaceuticals

Several institutional investors have recently made changes to their positions in XFOR. Acorn Capital Advisors LLC bought a new position in X4 Pharmaceuticals during the fourth quarter worth about $5,363,000. Geode Capital Management LLC lifted its position in shares of X4 Pharmaceuticals by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company’s stock worth $2,566,000 after buying an additional 49,700 shares during the period. State Street Corp boosted its stake in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after buying an additional 189,105 shares in the last quarter. Northern Trust Corp grew its position in X4 Pharmaceuticals by 2.9% in the fourth quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock valued at $996,000 after acquiring an additional 37,940 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in X4 Pharmaceuticals by 4.0% during the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after acquiring an additional 24,948 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock worth $91,198 over the last three months. Company insiders own 1.62% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.